Type 2 Diabetes Mellitus Completed Phase 4 Trials for Glyburide (DB01016)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus´╝îType 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

DBCOND0029752 (Type 2 Diabetes Mellitus)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01456650R230C and C230C Variants of ABCA1 and Glyburide ResponseBasic Science
NCT02318693Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)Treatment
NCT00123643Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic PatientsPrevention
NCT02145611Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and HypertensionTreatment
NCT02919345Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial ArteryTreatment
NCT03089333Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive SubjectsTreatment
NCT01045590Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes MellitusTreatment
NCT01605773Effect of Repaglinide on Postprandial Lipemia in Type 2 DiabetesTreatment
NCT01698931Efficacy of Repaglinide in Subjects With Type 2 DiabetesTreatment
NCT00347100Insulin Glargine in Type 2 Diabetic PatientsTreatment